CatalystMarker
Sign in
◆ Biotech catalyst intelligence

Catch the run-up.
Skip the coin-flip.

Every FDA & clinical catalyst, fused with smart-money positioning and a self-grading timing signal — so you ride the anticipation and exit before the binary.

PDUFAAd-commReadoutApprovalCRLBreakthroughFast TrackIPO
982 drug developers8,635 upcoming catalystsgraded in the open
RVMD $14.2B
Phase 3 · readout in 28d
readout
Timing signal
EXIT SOON
run-up +108% · near peak
Clinical signalAI⚗ exp
64% positive data
vs 58% base · advances/approves
breakthroughfast trackaccum 8/0
Clean data

Every US drug developer, deduped and dated

ClinicalTrials.gov, SEC 8-Ks and openFDA fused into one calendar — duplicates collapsed, each date carrying a confidence tier. Coverage you can trust.

Timing

Is the run-up still open, or priced in?

Our sell-the-news ladder places each catalyst on its anticipation curve — enter early, exit before the event. This is the validated edge.

Outcome

A probability, honestly labeled

Will the data read out positive — good enough to advance or win approval? Published base rates for each phase and disease area, with an experimental model lean on top, graded forward against real outcomes. Context on the science, never an oracle.

Proven, not promised

Everyone claims “AI predictions.”
We show whether ours were right.

We log every call before the event and grade it as the catalyst resolves — a live, public track record. The edges are honest: a real, modest tilt, not a crystal ball. That transparency is the whole point.

Base-rate
clinical odds anchored to phase × disease-area history
+16–20pp
entry-timing edge, ~30 days out
1,300+
resolved catalysts graded, no look-ahead
Open
methodology & caveats published

Everything in one place

Catalyst calendar

PDUFA, ad-comms, readouts and trial completions — filterable, dated, months ahead.

Entry-timing ladder

Where each catalyst sits on its run-up curve, right now: watch, enter, or already priced-in.

Outcome model

The odds a catalyst actually pops the stock — from what similar past catalysts did, plus how smart money is positioned.

Smart-money positioning

Short interest, insider buys/sells, and institutional accumulation per name.

IPO watch

Upcoming and just-priced biotech IPOs — filed, expected, and debuted.

Risk-reward screener

The strongest small/mid-cap setups, ranked — the coin-flip names filtered out.

The calendar is free. The edge is Pro.

Start with the near-term calendar and this month’s top catalyst. Go Pro for the signals, positioning, screener, and the live track record.